Sources: Andersen NB, et al
More realistic scenario: FDA approval 2028, commercial launch Q3-Q4 2028, shortages through early 2029, stable availability mid-2029
6.3 Clinical applications in cardiovascular disease prevention Recent American College of Cardiology/American Heart Association guidelines advocate for the use of GLP-1RAs in patients with T2DM at high risk of atherosclerotic cardiovascular disease (ASCVD), irrespective of well-controlled glucose levels, based on the clinical trials mandated by FDA-issued industry guidelines in December 2008 to assess the cardiovascular effects of new diabetic therapies (247)
However, these trends have also driven the development of new drugs to treat the disease
When your body doesnt have enough B12, you may experience symptoms such as tiredness, weakness, difficulty concentrating, and even mood changes
Testosterone provides the anabolic foundation that prevents muscle loss during caloric deficit and supports new tissue growth
.png)
